Laos, Malawi, Rwanda and Zambia Receive Oral Antiviral Treatments for High-Risk Patients Through COVID Treatment Quick Start Consortium
The COVID Treatment Quick Start Consortium announced today that the governments of Zambia, Laos, Malawi and Rwanda have received shipments of PAXLOVID™ (nirmatrelvir/ritonavir), Pfizer’s COVID-19 oral treatment. Partners involved in the Quick Start Consortium are supporting test-and-treat programs to improve access to antiviral treatments in low- and middle-income countries.
DCRI Highlights From ACC.23 Together With WCC
DCRI faculty and staff took part in more than 80 events at the 2023 American College of Cardiology Scientific Sessions (ACC.23), paired together with the World Congress of Cardiology (WCC). Events included late-breaking and featured presentations, panel discussions, debates, mentorship events, and moderated poster sessions. They covered topics ranging from interventional therapies, drug comparisons, and health equity research, to guideline adherence and preventive care.
Intervention Helps Clinicians Meet Guidelines for Prescribing Diabetes, Heart Drugs
Patients who have diabetes and heart disease do best when both conditions are treated according to established guidelines, but far too many are not prescribed the effective therapies. A recent study — designed and led by the Duke Clinical Research Institute (DCRI) and an academic steering committee — found that a coordinated care approach between cardiologists and diabetes specialists resulted in more patients receiving the recommended therapies. The study was funded by Boehringer Ingelheim and Eli Lilly and Company.
‘Don’t Miss a Beat’: DCRI’s Greene joins Brigham and Women’s Vaduganathan in monthly cardiology research podcast
Duke Clinical Research Institute cardiovascular faculty member Stephen Greene, MD, joins Brigham and Women’s cardi
EMPA-KIDNEY Trial shows benefits for CKD in broad range of patients
A recent trial of empagliflozin expanded the understanding of how the drug can slow chronic kidney disease in a wide range of patients, lowering the risk of disease progression and death from cardi
Forward Together: Locking in Team Culture
Duke Clinical Research Institute builds a lasting tradition around celebrating milestone moments
Study Confirms No Benefit to Taking Ivermectin for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between parti
Trial finds common malaria prevention regimen reduces complications of sickle cell anemia in Kenyan children
A study by the Duke Clinical Research Institute comparing three treatment methods of preventing malaria in children with sickle cell anemia (SCA) found one method reduces common complications of the disease. EPiTOMISE: Enhancing Preventive Therapy Of Malaria in Children with Sickle cell anemia in East Africa, was conducted among children with SCA in Homa Bay, Kenya, where malaria is common. It evaluated the effects of a monthly combination of sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) or a monthly combination of dihydroartemisinin-piperaquine (DP) against the standard of care in Kenya, Proguanil.
Duke STAR Program trains next generation of research professionals
The latest cohort of young researchers got a head start on learning the skills necessary to build a future in research over the summer, as they completed the Duke STAR program in August, 2022.
‘What should we do about Twitter?’
Following the recent organizational changes at Twitter and concerns about how they may affect the platform, DCRI Chief Science & Digital Officer Eric Perakslis, PhD, offers insights for clinicians and researchers who use the platform to share their work.